Shaperon Secures Japanese Patents for Papiliximab, Pioneering PD-L1/CD47 Bispecific Immunotherapy

News | 2025-10-24 15:04:37
[medi K / HEALTH IN NEWS] Shaperon, a South Korean biotechnology company, announced on Friday that three core technologies underpinning its next-generation immuno-oncology drug Papiliximab have been registered with the Japan Patent Office. With patents now secured in both South Korea and Japan, the company has established a robust global intellectual property framework across the two nations.

The newly registered patents cover a CD47 single-domain antibody, a PD-L1 single-domain antibody, and a PD-L1/CD47 bispecific antibody construct—material patents that form the foundational elements of Papiliximab. This positions Shaperon to hold exclusive rights in Japan until 2042 for the world's first NanoMab-based PD-L1×CD47 bispecific antibody platform, according to company officials. The firm plans to extend its patent filings to major markets including the United States, Europe, and China.

Papiliximab is an innovative cancer immunotherapy designed to simultaneously block the "don't eat me" signal from cancer cells via CD47 and the "don't kill me" signal via PD-L1, thereby activating both macrophages and T cells. While conventional CD47-targeting antibodies carry a risk of hemolysis due to red blood cell destruction, Shaperon's proprietary design circumvents this issue while delivering potent antitumor efficacy.

Shaperon CI (Photo courtesy of Shaperon)
Shaperon CI (Photo courtesy of Shaperon)


The underlying NanoMab platform features an ultra-small single-chain structure, roughly one-tenth the size of traditional antibodies. This enables superior penetration into cells and dense tumor tissues, along with enhanced production efficiency, formulation stability, and adaptability for multispecific antibody development. As a result, the platform is regarded as versatile for integration with next-generation therapeutics such as mRNA therapies, antibody-drug conjugates (ADCs), and radiopharmaceutical therapies (RPTs).

Shaperon maintains its own alpaca herd in Hongcheon, a rural county in South Korea's Gangwon Province, to generate NanoMab libraries. The company employs high-throughput phage display screening to rapidly identify candidate antibodies—a process that facilitates the discovery of novel sequences, performance validation, and strong patent positioning.

A Shaperon spokesperson stated: "Following domestic registration, the Japanese patents complete the global rights framework for Papiliximab. We will accelerate the worldwide commercialization of this next-generation immuno-oncology agent." The spokesperson added that the candidate offers superior safety and efficacy compared with existing immunotherapies, fundamentally resolving hemolytic toxicity to expedite global market entry.

Kim Kuk Ju / press@themedik.kr
Copyright © 2020 mediK. All rights reserved.